Antibiotic use in Crohn's disease: Why and how?

BioDrugs

Volumn 8, Issue 4, 1997, Pages 293-306

  Prantera, Cosimo ^a   Scribano, Maria Lia ^a   Berto, Eva ^a   Zannoni, Fabio ^a  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFALOTIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CLOFAZIMINE; COLISTIN; CORTICOSTEROID; COTRIMOXAZOLE; ERYTHROMYCIN; ETHAMBUTOL; ISONIAZID; METRONIDAZOLE; MINOCYCLINE; PYRAZINAMIDE; PYRIMETHAMINE; RIFABUTIN; RIFAMPICIN; SALAZOSULFAPYRIDINE; SULFADOXINE; TETRACYCLINE;

ANTIBIOTIC THERAPY; CROHN DISEASE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030763555     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199708040-00005     Document Type: Review

References (140)

1. Summers RW, Switz. DM, Sessions Jr JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69
2. Sandborn WJ, A review of immune modifier therapy tor inflammatory bowel disease: uzathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroemerol 1996; 91 (3): 423-33
3. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993; 17 (3): 235-7
4. Prantera C, Kohn A, Zannoni F, et al. Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: results of an open study, J Clin Gastroenterol 1994; 19 (1): 79-88
5. Paulley JW. A case of Whipple's disease (intestinal lipodystrophyl. Gastroenterology 1952; 22: 128-33
6. Mollin DR, Booth CC. Tropical sprue and megaloblastic anaemia. In: Wellcome Trust, editor. Wellcome Trust Collaborative Study, 1961-1969. Baltimore: Williams &Wilkins. 1971: 293-310
7. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med 1995; 122: 81-9
8. Kloppenburg M, Breedveld FC, Terwiel JP, et al. Minocyeline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994; 37: 629-36
9. Langevitz P, Bank I, Zemer D, et al. Treatment of resistant rheumatoid arthritis with minocycline: an open study. J Rheumatol 1992; 19: 1502-4
10. Lichtman SN. Wang J, Sartor RB, et al. Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: role of cytokines, bacteria and bacterial polymers. Infect Immun 1995; 63: 2295-301
11. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-32
12. Paulus HE. Minocycline treatment of rheumatoid arthritis. Ann Intern Med 1995; 122: 147-8
13. Rutgeerts P, Ghoos Y, Van Trappen G, et al. Heal dysfunction and bacterial overgrowth in patients with Crohn's disease. Eur J Clin Invest 1981; 11: 199-206
14. Sherman PM. Bacterial overgrowth. In: Yamada T. editor. Textbook of gastroenterology. New York: JB Lippincott, 1991: 1530-9
15. Burman JH, Thompson H, Cooke WT, et al. The effects of diversion of intestinal contents on the progress of Crohn's disease of the large bowel. Gut 1971; 12: 11-5
16. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-4
17. Marion JF, Lachman P, Greenslein AJ, et al. Rarity of fistulas in Crohn's disease of the jejunum. Inflamm Bowel Dis 1995; 1: 34-6
18. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perianal Crohn's disease with metronidazole. Gastroenterology 1980; 79: 357-65
19. Brandt LJ, Bernstein LH, Boley SS, et al. Metronidazole therapy for perianul Crohn's disease: a follow-up study. Gastroenterology 1982; 83: 383-7
20. Allan A, Keighley M. Management of perianal Crohn's disease. World J Surg 1988; 12: 198-202
21. Turunen U, Farkkila M, Valtonen V, et al. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease [abstract]. Gastroenterology 1993; 104: A793
22. Jukobovitis J, Shuster M. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984; 79: 533-40
23. Chiodini RJ, Van Kruiningen HJ, Merkal RS, et al. Ruminant paratuberculosis (Johne's disease): the current status and future prospects. Cornell Vet 1984; 74: 218-62
24. Morgan KL, Johne's and Crohn's: chronic inflammatory bowel diseases of infectious aetiology? Lancet 1987; II: 1017-9
25. Schneebaum CW, Novick DM, Chabon AB, et al. Terminal ileitis associated with Mycobacterium avium intracellular infection in a homosexual man with acquired immunodeficiency syndrome. Gastroenterology 1987; 92: 1127-32
26. Gray JR, Rabeneck L, Atypical mycobacterial infection of the gastrointestinal tract in AIDS patients. Am J Gastroenterol 1989; 84: 1521-4
27. Mayherry JF, Rhodes J, Heatley RV. Infections which cause ileocolic disease in animals: are they relevant to Crohns disease? Gastroenterology 1980; 78: 1080-4
28. Sutherland LR. Different patterns of Crohn's disease. In: Prantera C, Korelitz BI, editors, Crohn's disease, New York: Marcel Dekker, 1996: 201-15
29. Prantera C, Berto E, Seribano ML. Mycobacteria and subgroups of patients in Crohn's disease, Ital J Gastroenterol 1991; 23: 49-51
30. Van Kruiningen HJ, Colombel JF, Cartun RW, et al. An in-depth study of Crohn's disease in two French families, Gastroenterology 1993; 104: 351-60
31. Allan RN, Pease P, Ibhotson JP. Clustering of Crohn's disease in a Cotswold village. Q J Med 1986; 59: 473-8
32. Vantrappen G, Agg HO, Ponette E, et al. Yersinia enteritis and enterocolitis: gastroenterological aspects. Gastroenterology 1977; 72: 220-7
33. Elliott PR, Forsey T, Darougar S, et al. Chlamydiae and inflammatory bowel disease, Gut 1981; 22: 25-7
34. Willoughby JMT, Rahman AFM, Gregory MM. Chronic colitis after Aeromonas infection. Gut 1989; 30: 686-90
35. Roskell DE, Hyde GM, Campbell AP, et al. HIV associated cytomegalovirus colitis as a mimic of inflammatory bowel disease. Gut 1995; 37: 148-50
36. Liu Y, Van Kruiningen HJ, West AB, et al. Immunocytoehemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohns disease. Gastroenterology 1995; 108: 1396-404
37. Sartor RB, Rath HC, Sellon RK. Microbial factors in chronic intestinal inflammation, Curr Opin Gastroenterol 1996; 12: 327-33
38. Brown WR. Listeria: the latest putative pathogenetic microorganism in Crohns disease, Gastroenterology 1995; 108: 1589-90
39. Chiodini RJ, Van Kruiningen HJ, Merkal RS et al. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease. J Clin Microbiol 1984; 20: 966-71
40. Chiodini RJ, Van Kruiningen HJ, Thayer WR, et al. Possible role of mycobacteria in inflammatory bowel disease: I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 1984; 29: 1073-9
41. Thayer WR, Coutu JA, Chiodini RJ, et al. Possible role of mycobacteria in inflammatory bowel disease: II. Mycobacterial antibodies in Crohn's disease. Dig Dis Sci 1984; 29: 1080-5
42. Chiodini RJ, Van Kruiningen HJ, Thayer WR, et al. Spheroplastic phase of Mycobacteria isolated from patients with Crohns disease. J Clin Microbiol 1986; 24: 357-63
43. Elasaghier A, Prantera C, Moreno C, et al. Antibodies to Mycobacterium paratuberculosis-specific protein untigens in Crohn's disease, Clin Exp Immunol 1992; 90: 503-8
44. Elsaghier A, Prantera, C, Bothamley G, et al. Disease association of antibodies to human and mycobacterial hsp 70 and hsp 60 stress proteins, Clin Exp Immunol 1992; 89: 305-9
45. Cho SN, Brennun PJ, Yoshimura HH, et al. Mycobacterial actiology of Crohn's disease: serologic study using common mycobacterial antigens and a species-specific glycolipid antigen from Mycobacterium paratuberculosis Gut 1986; 27: 1353-6
46. Graham DY, Markesich DC, Yoshimura HH. Mycobacteria and inflammatory bowel disease: results of culture, Gastroenterology 1987; 92: 436-42
47. Butcher PD, McFadden JJ, Hermon-Taylor J. Investigation of mycobacteria in Crohn's disease tissue by Southern blotting and DNA hybridization with cloned mycobacterial genomic DNA probes from a Crohn's disease isolated mycobacteria, Gut 1988; 29: 1222-8
48. Kohayashi K, Blaser MJ, Brown WK, Immunohistochemical examination for mycobacteria in intestinal tissues from patients with Crohn's disease. Gastroenterology 1989; 96: 1009-15
49. Stainsby KL, Lowes JR, Allan RN, et al. Antibodies to Mycobacterium paratuberculosis and nine species of environmental Mycobacteria in Crohn's disease and control subjects. Gut 1993; 34: 371-4
50. Van Kruiningen HJ, Chiodini RJ, Thayer WR, et al. Experimental disease in infant goats induced by a mycobacterium isolated from a patient with Crohn's disese: a preliminary report. Dig Dis Sci 1986; 31: 1351-60
51. Bradford Hill A. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300
52. Glynn JR. A question of attribution. Lancet 1993; 342: 530-2
53. Ward M, McManus JPA. Dapsone in Crohn's disease. Lancet 1975; 1: 1236-7
54. Warren JB, Rees HC, Cox TM. Remission of Crohn's disease with tuberculosis chemotherapy. N Engl J Med 1986; 314: 182
55. Schultz MG, Rieder HL, Hersh T, et al. Remission of Crohn's disease with antimycobacterial chemotherapy. Lancet 1987; II: 1391-2
56. Prantera C, Argentieri R, Mangiarotti R, et al. Dapsone and remission of Crohn's disease. Lancet 1988; II: 536
57. Prantera C, Bothamley G, Levenstein S, et al. Crohn's disease and mycobacteria: two cases of Crohn's disease with high antimycobacterial antibody levels cured by dapsone therapy. Biomed Pharmacother 1989; 43: 295-9
58. Paris JC, Simon V, Paris J. Etude critique des effects de la medication antituberculeuse dans une série de 52 cas de formes sévères de la maladie de Crohn. Ann Gastroentérol Hepatol (Paris) 1977; 13: 427-33
59. Toulet J, Rousselet J, Viteau M. La rifampicine dans le traitement de la maladie de Crohn. Gastroenterol Clin Biol 1979; 3: 209-11
60. Elliot PR, Burnham WR, Berghouse LM, et al. Sulphadoxine-pyrimethamine therapy in Crohn's diseaese. Digestion 1982; 23: 132-4
61. Burnham WR, Lennard-Jones JE, Stanford JL, et al. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet 1978; 2: 693-6
62. Shaffer JL, Hughes S, Linker B, et al. Controlled trial of rifampiein and ethambutol in Crohn's disease. Gut 1984; 25: 203-5
63. Hampson SJ, Parker MC, Saverymuttu SH, et al. Quadruple antimycobacterial chemotherapy in Crohns disease: results at 9 months of a pilot study in 20 patients. Aliment Pharmacol Ther 1989; 3: 343-52
64. Swift GL, Srivastava ED, Stone R, et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994; 35: 363-8
65. Best WR, Bektel JM, Singleton JW, et al. Development of a Crohns Disease Activity Index: National Cooperative Crohns Disease Study. Gastroenterology 1976; 70: 439-44
66. Afdhal NH, Long A, Lennon J, et al. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci 1991; 36: 449-53
67. Prunteru C, Kohn A, Mangiarotti R, et al. Antimycobacterial therapy in Crohn's disease: results of a controlled, doubleblind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513-8
68. Pines AE, Cosnes J, Carbonnel F, et al. Le lamprene dans les localisations ano-perineales de lu maladie de Crohn: un etude retrospective. Ann Gastroenterol Hepatol (Paris) 1993; 29: 155-63
69. Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohns disease following therapy for Mycobacterium paratuberculosis |abstract]. Gastroenterology 1995; 108: A826
70. Rutgeerts P, Geboes K, Vantrappen G, et al. Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. J Clin Gustroenterol 1992; 15: 24-8
71. Basilisco G, Ranzi T, Campanini C, et al. Controlled trial of rifabutin in Crohn's disease. Curr Ther Res 1989; 46: 242-50
72. Prantera C. Comment to: the role of antibiotics in Crohn's disease. In: Prantera C. Korelitz BI, editors. Crohn's disease. New York: Marcel Dekker, 1996; 411-2
73. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89: S116-28
74. LaMont JT, Trnku YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 1980; I: 381-3
75. Newman A, Lampert JR. Campylobacter jejuni causing flareup in inflammatory bowel disease. Lancet 1980; II: 919
76. Skirrow MB. Campylobacter, Salmonella, Shigella and other acute bacterial disorders. In: Allan RN, Keighley MRB, Alexander-Williams J, et al., editors. Inflammatory bowel disease. Edinburgh: Churchill Livingstone, 1983: 595-607
77. Seaver RL. Screening for Clostridium difficile in chronic inflammatory bowel disease in relapse: is it helpful? is it cost efficient? J Clin Gastroenterol 1986; 8: 397-400
78. Ambrose NS, Allan RN, Keighley MRB, et al. Antibiotic therapy for treatment in relapse of intestinal Crohns disease: a prospective randomized study. Dis Colon Rectum 1985; 28: 81-5
79. Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse in chronic bowel disease. Gastroenterology 1981; 80: 693-6
80. Sartor RB. Role of intestinal microflora in initiation and perpetuation of inflammatory bowel disease. Can J Gastroenterol 1990; 4 (7): 271-7
81. Horing E, Gopfert D, Schroter G, et al. Frequency and spectrum of microorganisms isolated from biopsy specimens in chronic colitis, Endoscopy 1991; 23: 325-7
82. Weber P, Koch M, Heizmann WR, et al. Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol 1992; 14 (4): 302-8
83. Meyers S, Mayer L, Bottone E, et al. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology 1981; 80: 697-700
84. Kirschner BS, Does acute infection trigger chronic inflammation in pediatric patients with chronic inflammatory bowel disease? Gastroenterology 1993; 104: A725
85. Blaser MJ, Miller RA, Lacher J, et al. Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 1984; 87: 888-94
86. Kangro HO, Chong SKF, Hardiman A, et al. A prospective study of viral and mycoplasma infections in chronic intlammatory bowel disease. Gastroenterology 1990; 98: 549-53
87. Blumberg RS. Relapse of chronic inflammatory bowel disease: 'a riddle wrapped in a mystery inside an enigma'. Gastroenterology 1990; 98: 792-6
88. Ambrose NS, Johnson M, Burdon DW, et al. Incidence of pathogenic bacteria from mesenteric lymph nodes and Meal serosa during Crohn's disease surgery. Br J Surg 1984; 71: 623-5
89. Berg RD. Bacterial translocation from the gastrointestinal tract. J Med 1992; 23: 217-44
90. Spaeth G, Specian RD, Berg RD, et al. Bulk prevents bacterial translocation induced by the oral administration of total parenteral nutrition solution. J Parent Enter Nutr 1990; 14: 442-7
91. Shou J, Lappin J, Minuard EA, et al. Total paremeral nutrition, bacterial translocation and host immune function. Am J Surg 1994; 167: 134-50
92. Prizont R, Hersh T, Floch MH. Jejunal bacterial flora in chronic small bowel disease. Am J Clin Nutr 1970; 23: 1602-7
93. Beeken WL, Kanich RE. Microbial flora of the upper small bowel in Crohn's disease. Gastroenterology 1973; 65: 390-7
94. Ursing B, Kamme C. Metronidazole for Crohn's disease. Lancet 1975; I: 775-7
95. Bockus HL. Regional enteritis. In: Gastroenterology. Vol. 2. sect V. Philadelphia: W.B. Saunders, 1976: 574-8
96. Videla S, Vilaseca J, Salas A, et al. Key role of intestinal microflora in sustaining chronic inflammation of the rat colon. Gastroenterology 1993; 104: A797
97. Abreu MT, Targan SR. The future of Crohns disease: new developments in etiopathogenesis and therapeutics. In: Prantera C. Korelitz BI, editors. Crohns disease. New York: Marcel Dekker, 1996: 561-86
98. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives: a possible etiologic factor. Ann Intern Med 1986: 105: 883-5
99. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341: 1437-9
100. Keighley MRB, Arabi Y, Dimock F, et al. Influence of inflammatory bowel disease on intestinal microflora. Gut 1978; 19: 1099-104
101. Wensinck F, Custers van Lieshoout LMC. Poppelaars Kustermans PAJ, et al. The faecal flora of patients with Crohn's disease. J Hyg Camb 1981; 87 (1): 1-12
102. Van De Merwe J, Schroder AM, Wensinck F, et al. The obligate anaerobic faecal flora of patients with Crohn's disease and their first-degree relatives. Scand J Gastroenterol 1988; 23: 1125-31
103. Burke DA, Axon ATR. Adhesive Excherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ 1988; 297: 102-4
104. Tabaqchali S, O'Donoghue DP, Bettelheim KA. Escherichia coli antibodies in patients with inflammatory bowel disease. Gut 1978; 19: 108-13
105. Brown WR, Lee E. Radioimmunological measurements of bacterial antibodies: II. Human serum antibodies reactive with Bactemides fragilis and enterococcus in gastrointestinal and immunological disorders. Gastroenterology 1974; 66: 1145-53
106. Macpherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38: 365-75
107. Fiocchi C. Overview of inflammatory bowel disease pathogenesis. Can J Gastroenterol 1990; 4: 309-16
108. Gardiner KR, Halliday MI, Barclay GR, et al. Significance of systemic endotoxaemia in inflammatory bowel disease, Gut 1995; 36: 897-901
109. Hudson MJ, Hill MJ, Elliot PR, et al. The microbial flora of the rectal mucosa and faeces of patients with Crohn's disease before and during antimicrobial chemotherapy. J Med Microbiol 1984; 18: 335-45
110. Saverymuttu S, Hodgson HJF, Chadwick VS. Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease. Gut 1985; 26: 994-8
111. Moss AA, Carbone JV, Kressel HY. Radiologic and clinical assessment of hroad-spectrum antibiotic therapy in Crohn's disease. Am J Roentgenol 1978; 1311: 787-90
112. Dickinson RJ, O'Connor HJ, Finder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380-4
113. Danzi JT. Trimethoprim-sulphamethoxazole therapy of inflammatory bowel disese [abstract]. Gastroenterology 1989; 96: A110
114. Gradon JD, Zimbalist EH. Is trimethoprim-sulfamethoxazole helpful in Crohn's disease? J Clin Gastroenterol 1990; 12: 598-607
115. Blichfeldt P, Blomhoff JP, Myhre E, et al. Metronidazole in Crohn's disease: a double blind cross-over clinical trial. Scand J Gastroenterol 1978; 13: 123-7
116. Rosen A, Ursing B, Alm T, et al. A comparative study of melroniduzole and sulfasalazine for active Crohn's disease: the Cooperative Crohn's Disease Study in Sweden: I. Design and methodologic considerations, Gastroenterology 1982; 83: 541-9
117. Ursing B, Alm T, Burany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the Cooperative Crohn's Disease Study in Sweden: II. Result. Gastroenterology 1982; 83: 550-62
118. Meyers S, Janowitz HD. 'Natural history' of Crohn's disease: an analytic review of the placebo lesson. Gastroenterology 1984; 87: 1189-92
119. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-5
120. Bernstein CN, Shunahan F. Metroniduzole in Crohn's disease: what's the score? Gastroenterology 1992; 102: 1435-6
121. Goldman P, Metronidazole. N Engl J Med 1980; 303: 1212-8
122. Krook A, Lindstrom B, Kjellunder J, et al. Relation between concentrations of metronidazole and Bacteroides sp, in faeces of patients with Crohn's disease and healthy individuals. J Clin Pathol 1981; 34: 645-50
123. Gorbach SL. Viral infections and inflammatory bowel disease. Gastroenterology 1982; 83: 1318-9
124. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-21
125. Murgolis PS, Thuyer WR, The role of antibiotics in Crohn's disease. In: Prantera C, Korelitz BI, editors. Crohn's disease. New York: Marcel Dekker. 1996: 401-12
126. Bradley WG, Karlsson IJ, Rassol CG. Metronidazole neuropathy. BMJ 1977; 3: 610-1
127. Duffy L, Daum F, Fisher S, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole, Gustroenterology 1985; 88: 681-4
128. Rustia M, Shubik P. Induction of lung tumors and malignant lymphomas in mice by metronidazole. J Natl Cancer Inst 1972; 48: 721-9
129. Nord CE, Effect of quinolones on the human intestinal microflora. Drugs 1995; 49 (Suppl, 2): KI-5
130. Sanders CC, Sanders WE, Goerging RV, Overview of preclinical studies with ciprofloxcin. Am J Med 1987; 82: 2-11
131. Norel CE, Effect of new quinolones on the human gastrointestinal microflora. Rev Infect Dis 1988; 10 (Suppl. 1): 5193-6
132. Brumfitt W, Franklin I, Grady D, et al. Changes in the pharmacokinetics of ciprofloxacin and faecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 1984; 26: 757-61
133. Chiodini RJ. Bacterial activities of various antimicrobial agents against human and animal isolates of Mycobacterium paratuberculosis, Antimicrob Agents Chemother 1990; 34: 366-7
134. Pichler HET, Diridl G, Stickler K, et al. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea, Am J Med 1987; 82 (Suppl. 4A): 329-32
135. Ericsson CD, Johnson PC, Dupont HI., et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea: a placebo-controlled, randomized trial, Ann Intern Med 1987; 106: 216-20
136. Taylor DN, Sunchez JL, Candler W, et, al. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone, a placebo-controlled, randomized trial. Ann Intern Med 1991; 114: 731-4
137. Wolf JL. Ciprofloxacin may be useful in Crohn's disease [abstract], Gastroenterology 1990; 98: A212
138. Greenbloom SL, Steinhart AH, Greenberg GR, et al. Ciprofloxacin and metronidazole: combination antibiotic therapy for ileocolonic Crohn's disease (abstract). Clin Invest Med 1995; 18(A): 48
139. Turunen U, Farkkila M, Hakala K, et al. Ciprofloxacin treatment combined with conventional therapy in Crohn's disease: a prospective, double blind, placebo controlled study [abstract]. Gut 1995; 37(A): 193
140. Katz JA, Fiocchi C, Causes and mechanisms of Crohn's disease. In: Prantera C, Korelitz BI, editors. Crohn's disease, New York: Marcel Dekker, 1996: 9-56